BlackRock, Inc. 13D and 13G filings for Albireo Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-08 2:01 pm Sale | 2023-02-28 | 13G | Albireo Pharma, Inc. ALBO | BlackRock Inc. BLK | 506,425 2.400% | -838,472 (-62.34%) | Filing |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Albireo Pharma, Inc. ALBO | BlackRock Inc. BLK | 1,344,897 6.500% | 176,114 (+15.07%) | Filing |
| 2022-02-02 7:11 pm Sale | 2021-12-31 | 13G | Albireo Pharma, Inc. ALBO | BlackRock Inc. BLK | 1,168,783 6.100% | -73,997 (-5.95%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Albireo Pharma, Inc. ALBO | BlackRock Inc. BLK | 1,242,780 6.500% | 556,324 (+81.04%) | Filing |